Background: Icotinib has been previously shown to be non-inferior to gefitinib in non-selected advanced non-small-cell lung cancer patients when given as second-or further-line treatment. In this open-label, randomized, phase 3 CONVINCE trial, we assessed the efficacy and safety of first-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance in lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) mutation.
Introduction
Lung cancer is a major health burden worldwide, with estimated 2.2 million new cases and 1.6 million deaths per year [1] . Nonsmall-cell lung cancer (NSCLC) accounts for >80% of all lung cancers, of which 50% of patients present with advanced disease at diagnosis. The standard chemotherapy for NSCLC patients with advanced disease (stage IIIB or IV) is platinum-based doublets. A randomized phase III study has demonstrated that cisplatin/ pemetrexed significantly improved overall survival (OS) in patients with advanced lung adenocarcinoma compared to cisplatin/gemcitabine [2] . More recently, pemetrexed maintenance after cisplatin/ pemetrexed conferred superior progression-free survival (PFS) and OS benefits versus cisplatin/pemetrexed alone [3, 4] . These findings make pemetrexed-based chemotherapy a preferential regimen for non-squamous NSCLC, especially lung adenocarcinoma.
Epidermal growth factor receptor (EGFR) is one of the most important molecule biomarkers in NSCLC, in which mutations strongly predict the efficacy and sensitivity to EGFR tyrosine kinase inhibitors (TKIs) [5] [6] [7] . EGFR TKIs have been demonstrated to provide better clinical efficacy and safety compared with chemotherapy when given as first-line therapy for advanced NSCLC patients with EGFR mutations [8] [9] [10] . However, no study so far has compared EGFR TKIs with pemetrexed-based chemotherapy plus maintenance.
Icotinib is a potent, orally available, highly selective EGFR TKI [11] . A phase III clinical study revealed icotinib was non-inferior to gefitinib in efficacy with favorable safety in non-selected or EGFR-mutant NSCLC patients when given as second-or furtherline treatment [12] . The safety of icotinib in a broad range of patients with advanced NSCLC was further confirmed in a phase 4 study [13] . The CONVINCE study was initiated to compare the efficacy and safety of first-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance in patients with advanced lung adenocarcinoma harboring activating EGFR mutations.
Patients and methods

Patient eligibility
This phase 3, open-label, randomized study was conducted at 18 sites in China. Full details could be found in the protocol (supplementary file, available at Annals of Oncology online). Eligible patients were histologically confirmed stage IIIB or IV lung adenocarcinoma (AJCC TNM version 7) with activating EGFR mutations (exon 19 deletion or L858R mutation in exon 21) assessed by the central laboratory using the amplification refractory mutation system (ARMS; Therascreen EGFR Mutation Test kit, Qiagen Manchester Ltd., Manchester, UK). Inclusion criteria also included: age older than 18 years, no history of chemotherapy for metastatic disease, measurable lesion according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1, an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-2, and adequate organ function. Patients were not eligible if they had non-adenocarcinoma or negative EGFR mutation, uncontrolled brain metastases, and serious lung or cardiac disease, or had received previous systemic anticancer therapy for advanced disease.
Study design
Patients were randomly allocated (1 : 1) to receive oral icotinib (125 mg three times per day) or 3 week cycles of intravenous chemotherapy (75 mg/m 2 cisplatin plus 500 mg/m 2 pemetrexed on day 1); nonprogressive patients after 4 cycles of chemotherapy were maintained with pemetrexed, until progressive disease (PD) or unacceptable toxicity. The first dose was designed to be administered within 7 days of randomization. Randomization was done centrally by Department of Medical Statistics of the Fourth Military Medical University of Chinese PLA using an interactive web-based randomization system. Stratification factors were ECOG PS, smoking status, disease stage, and mutation type. Neither physicians nor patients were masked to treatment assignment. Dose reductions of chemotherapy were done if necessary. Dose reductions of icotinib were not recommended, but treatment was allowed to be interrupted for up to 14 days if grade 3 or 4 adverse events (AEs) were observed. Patients were withdrawn from the study if the AEs were not recovered to grade 1 or 2 after treatment interruption. Post-progression crossover was at the physician's discretion.
The study was undertaken in accordance with the Declaration of Helsinki, and Good Clinical Practice guidelines. The protocol was approved by the ethics review board of every participating institution, and all patients provided written informed consent. An independent response evaluation committee (IREC) primarily reviewed efficacy and safety data.
Assessments
Radiographic assessments were performed at baseline and every 6 weeks until PD according to RECIST version 1.1. After PD, survival information was collected every 12 weeks until death or withdrawal of study consent. The primary end point was PFS. Secondary end points were OS, AEs and treatment-related AEs (graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0).
Statistics analysis
The sample size was 270 patients, have a power of 85% to detect a hazard ratio (HR) of 0.64 with a two-sided alpha of 0.05. Assuming a median PFS of 11 months with icotinib (based on the data from gefitinib and erlotinib), compared with 7 months for chemotherapy plus pemetrexed maintenance [2] [3] [4] [8] [9] [10] , and a 12-month accrual period and 24-month follow-up.
Cox proportional-hazards model was used to estimate HR and 95% confidence interval (95% CI). For superiority to be demonstrated, the 95% CI for the HR had to lie below the predefined superiority limit of 1, and the P value had to be <0.05. Median PFS and OS were calculated using Kaplan-Meier method, and compared between groups using the log-rank test. Data were analyzed with SAS statistical software (version 9.4).
Preplanned subgroup analyses were performed to compare PFS between treatment groups, stratified by ECOG PS, smoking status, disease stage, and mutation type.
AEs and treatment-related AEs were collected for all patients who received at least one dose of assigned study medication. The incidence rates were compared using Fisher's exact test. 
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Results 669 patients were screened between 7 January 2013 and 25 August 2014. 296 eligible patients with EGFR mutations were enrolled and randomly assigned to icotinib (N ¼ 148) or cisplatin/ pemetrexed plus pemetrexed maintenance (N ¼ 148; Figure 1 ). Among patients in the chemotherapy group, 11 did not receive any study treatment; therefore, the safety and efficacy set comprised 285 patients (148 for the icotinib arm, and 137 for the chemotherapy arm; Figure 1 ). Baseline characteristics including age, gender, disease stage, recurrent versus metastasis, and the presence of brain metastasis were balanced in both arms (Table 1) .
Efficacy
The cutoff date for PFS data was 9 March 2016. Median duration of follow-up was 18.0 and 15.7 months for the icotinib and chemotherapy arms, respectively. 111 out of 137 patients in the chemotherapy group completed 4 cycles of cisplatin/pemetrexed, and received pemetrexed maintenance with a median number of 5 cycles (range 1-35). At the cutoff, 202 patients had PFS events (200 PD, and 2 deaths). Median PFS assessed by IREC was 11.2 and 7.9 months for the icotinib and chemotherapy arms, respectively (HR, 0.61, 95% CI 0.43-0.87; P ¼ 0.006; Figure 2A ). Investigator-assessed median PFS yielded similar results (9.9 months versus 7.3 months; HR, 0.65, 95% CI 0.48-0.88; P ¼ 0.005; Figure 2B ). There was no significant difference in PFS among patients harboring 19 Del (icotinib versus chemotherapy: 11.2 months versus 8.0 months; HR, 0.66, 95% CI 0.38-1.14; P ¼ 0.136; Figure 2C ) or 21 L858R (icotinib versus chemotherapy:
11.1 months versus 7.8 months; HR, 0.76, 95% CI 0.43-1.33; P ¼ 0.331; Figure 2D ) under different treatments. The HR favored icotinib arm across most subgroups stratified by clinical factors ( Figure 2E and F).
The cutoff date for OS data was 10 March 2017, with a median follow-up of 39.6 months (range 12.4-50.8). About 172 patients had OS events (89 for the icotinib arm, 83 for the chemotherapy arm). Median OS did not differ significantly in overall population (icotinib versus chemotherapy: 30.5 months versus 32.1 months; log-rank P ¼ 0.8854), or in patients harboring 19 Del (icotinib versus chemotherapy: 32.3 months versus 38.8 months; log rank P ¼0.4066) or 21 L858R (icotinib versus chemotherapy: 29.1 months versus 26.7 months; log rank P ¼ 0.5259) (Figure 3 ). Patients with brain metastasis had a lower OS compared to patients without brain metastasis when receiving either icotinib or chemotherapy (supplementary Figure S1 , available at Annals of Oncology online), whereas, no statistically difference was found. In a multivariable analysis of OS, clinical factors including ECOG PS, gender, smoking status, mutation type, and disease stage were not predictors for OS (supplementary Table S1 , available at Annals of Oncology online). Patients with ECOG PS 2 were included in this study and evaluated by physicians before treatment, and in fact, they all tolerated well under cisplatin/pemetrexed.
Post-protocol treatments were summarized in supplementary Table S2 available at Annals of Oncology online. There was no restricted rule of post-progression crossover in this study protocol. A total of 193 patients received at least one subsequent treatment after PD (94 for the icotinib arm, and 99 for the chemotherapy arm): 82 of 99 (82.8%) patients in the chemotherapy group received EGFR TKIs, primary icotinib. On the other hand, 87 of 94 (92.5%) patients in the icotinib arm received chemotherapy or other EGFR TKIs (53 for different regimens of chemotherapy, 14 for EGFR TKIs except icotinib, and 20 for other systemic treatments). The percentage of patients receiving post-progression treatments was comparable between the two arms.
Safety
The median duration of treatment was 10.0 months for the icotinib group and 7 cycles for the chemotherapy group. The most common AE was rash for icotinib, and hematologic and gastrointestinal toxicities for chemotherapy (Table 2) . Chemotherapy was associated with more grade 3 or 4 AEs (24.8% versus 9.5%; P ¼ 0.001), treatment-related grade 3 or 4 AEs (23.4% versus 4.7%; P < 0.001) than icotinib. Dose modification in the chemotherapy arm was 10 (7.3%) for cisplatin and 14 (10.2%) for pemetrexed. AEs leading to drug discontinuation were 3 (2.0%) in the icotinib arm versus 24 (17.5%) in the chemotherapy arm. The average dose intensity of cisplatin and pemetrexed was 24.3 and 164.9 mg/m 2 /w, respectively.
Discussion
To the best of our knowledge, this study provides the first direct evidence for the superiority of icotinib over first-line cisplatin/ pemetrexed plus pemetrexed maintenance in untreated patients 14 (5) 28 ( Figure 2 . PFS analysis in the overall population and EGFR-mutated subgroups. Kaplan-Meier curves for PFS between icotinib and chemotherapy in the overall population assessed by IREC (A) and investigator (B), and in patients harboring EGFR exon 19 deletion (C) and exon 21 L858R point mutation (D) assessed by IREC. The forest plots of PFS in subgroups stratified by clinical factors which assessed by IREC (E) or investigator (F). PFS, progression-free survival; IREC, independent response evaluation committee; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor.
with EGFR mutation-positive lung adenocarcinoma. Icotinib conferred a significant PFS advantage assessed by both IREC and investigators, along with a better safety profile, compared with first-line chemotherapy. Similar to previous studies comparing EGFR TKIs with chemotherapy, OS was similar between icotinib and chemotherapy.
The logics of selecting cisplatin/pemetrexed plus pemetrexed maintenance as the control arm of our study: Icotinib has shown a non-inferior efficacy to gefitinib as second-and third-line treatment of EGFR-mutant NSCLC patients [12] ; Erlotinib had not been approved by the China Food and Drug Administration (CFDA) in first-line setting at that time. Afatinib was approved for the first-line treatment of EGFR-mutated NSCLC patients by the U.S. FDA in July 2013, whereas this study was initiated in 2012. Moreover, cisplatin/pemetrexed plus pemetrexed maintenance conferred superior survival benefits for non-squamous NSCLC patients compared with other chemotherapy regimens [3, 4] . Limited data were available to assess the application of pemetrexed maintenance in non-squamous NSCLC patients with EGFR mutations.
As compared with standard chemotherapy, first-line treatment of icotinib resulted in similar magnitude of improvement in PFS as other studies evaluating first-and second-generation EGFR TKIs in patients with activating EGFR mutation (8.4-13.1 months) [8] [9] [10] . We found in this study that icotinib was associated with a prolonged PFS versus chemotherapy in patients stratified by 19 Del or 21 L858R. It is known that exon 19 Del and 21 L858R constitute 90% of total EGFR mutations [14] . Despite of similar sensitivity to EGFR TKIs, it has been suggested that patients with 19 Del was associated with greater PFS benefit from EGFR TKIs than patients harboring 21 L858R [10] . In this study, we found that patients harboring 19 Del had a slightly longer PFS compared to patients with 21 L858R after treated with icotinib; however, the difference was not statistically significant probably because of the small sample size in each group.
In CONVINCE, icotinib showed similar OS benefit as compared with chemotherapy in the overall population or in patients harboring 19 Del or 21 L858R, which was consistent with other randomized studies evaluating first-generation EGFR TKIs like gefitinib and erlotinib [15, 16] . The main explanation of the similar OS results is that the benefit from EGFR TKIs may offset by subsequent treatments post-progression as 92.5% of the icotinib arm received further treatment with chemotherapy or other EGFR TKIs versus 82.8% of the chemotherapy arm received poststudy EGFR TKIs.
The safety of icotinib and pemetrexed-based regimen in our study was consistent with prior studies [2-4, 12, 13] . No new safety signal was reported. The frequency of icotinib-related AEs in CONVINCE (54.1%) was similar to that in ICOGEN (61.0%) [12] . Both icotinib and chemotherapy were well-tolerated, whereas pemetrexed-based chemotherapy was associated with more AEs than icotinib. Icotinib-induced interstitial lung disease (ILD) was occurred in patients who have received at least one platinum-based chemotherapy [13, 17] Months Figure 3 . OS analysis in overall population and EGFR mutation subgroups. Kaplan-Meier curves for OS between icotinib and chemotherapy in the overall population (A), and patients harboring EGFR exon 19 deletion (B) or exon 21 L858R point mutation (C). OS, overall survival; EGFR, epidermal growth factor receptor; CI, confidence interval. 
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Data are expressed as n (%). AEs, adverse events; ALT, alanine transaminase; AST, aspartate transaminase.
this study, we believe that this was due to the first-line use of icotinib for lung adenocarcinoma patients. Key strength of CONVINCE study was the introduction of pemetrexed maintenance into the chemotherapy comparator. The PFS for the chemotherapy arm of this study (7.9 months by IREC, and 7.3 months by investigator) exceeded that of the PARAMOUNT trial (6.9 months), and other randomized studies conducted in never-treated patients with activating EGFR mutation (4.6-6.9 months) [8] [9] [10] . Additionally, to the best of our knowledge, this is the only study to date to present both PFS and OS of cisplatin/pemetrexed plus pemetrexed maintenance therapy in advanced lung adenocarcinoma patients with activating EGFR mutation. These findings were bound to provide valuable reference for further clinical investigations.
One limitation of this study is the lack of re-biopsy for patients with PD, to assess mechanisms for resistance for icotinib. Considering patients' willingness for re-biopsy, which was not a standard clinical procedure when this study was designed, rebiopsy for progressive patients was beyond the major scope in this study. Additionally, currently icotinib is only clinically available in China, and requires thrice-daily administration, which might bring inconvenience to patients. However, icotinib is associated with less toxicity, economic efficiency, and equivalent efficacy compared with other EGFR TKIs [18] [19] [20] , which is of great importance for fulfilling the growing demand for treatment of advanced NSCLC in China.
In conclusion, our study shows that icotinib can provide better efficacy and fewer side-effects compared with first-line chemotherapy of cisplatin/pemetrexed plus pemetrexed maintenance in untreated advanced lung adenocarcinoma patients with EGFR mutation. Icotinib should therefore be considered as a standard first-line treatment option for this patient population.
